IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:37945-0009

pplicant:

BRUGGEMANN, Marianne

Confirmation No.: 3627

Appl. No.:

09/734,613

Examiner: Not yet assigned

Filing Date:

December 13, 2000

Art Unit: 1651

Title:

MURINE EXPRESSION OF A HUMAN IGA LAMBDA LOCUS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Director of Patents Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99. A complete copy of reference A33 was unavailable at the time of filing this Information Disclosure Statement. The applicant will submit a copy of this reference in due course.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

The attached documents were cited in the search report of a corresponding International application and/or in connection with the prosection of the corresponding United Kingdom application.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Date: 5-21-01

HELLER EHRMAN WHITE & MCAULIFFE 1666 K Street, N.W., Suite 300

Washington, DC 20006

Telephone:

(202) 912-2777

Facsimile:

(202) 912-2020

By (/ Ma / Y < 1

Respectfully submitted,

John P. Isacson

Attorney for Applicant Registration No. 33,715

Customer No. 26633

26633

PATENT TRADEMARK OFFICE

Please type a plus sign (*) inside this box

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 7

	Complete if Known	
Application Number	09/734,613	
Filing Date	December 13, 2000	
First Named Inventor	BRUGGEMANN; Marianne	
Group Art Unit	1651	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	37945-0009	

				U.S. PATENT DOCUM	MENTS	<u> </u>
		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevan
Examiner (Initials * 1	Cite No. ¹	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

		····		FOREIGI	N PATENT DOCU	MENTS		<u></u>
Examiner Initials*	Cite No.1	For Office ³	KIIIMAAF	ment ind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ₆
	A01	WO	98/24884	/	Genpharm	06-11-1998		
	A02	wo	92/04443	/	President and Fellows of Harvard College	03-19-1992		
· · · · · · · · · · · · · · · · · · ·	A03	WO	98/24893	/	Abgenix Inc.	06-11-1998		
	A04	wo	93/05165	1	Agriculture and Food Research Council	03-18-1993		
-								
		 						
		-						ļ
				1				

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

Please type a plus sign (*) inside this box U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO 09/734,613 **Application Number INFORMATION DISCLOSURE** December 13, 2000 Filing Date STATEMENT BY APPLICANT BRUGGEMANN, Marianne First Named Inventor Group Art Unit 1651 Not Yet Assigned (use as many sheets as necessary) **Examiner Name** 37945-0009 Attorney Docket Number of 7 2 Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
macio	A05	POPOV, A et al, "Assembly and Extension of Yeast Artificial Chromosomes to Build a Large Locus"; Gene: An International Journal on Genes and Genomes; October 24, 1996; pages 195-201; Vol. 177, No. 1; Elsevier Science Publishers, Great Britain	
	A06	GORMAN, J. et al; "The Igκ 3' Enhancer Influences the Ratio of Igκ Versus Igλ B Lymphocytes"; Immunity; September 1996; pages 241-252; Vol. 5, No. 3; Cell Press	
	A07	POPOV, A et al; "A Human Immunoglobulin λ Locus Is Similarly Well Expressed in Mice and Humans"; J. Exp. Med; May 17, 1999; pages 1611-1620; Vol. 189, No. 10; The Rockefeller University Press	
	A08	HOOD, L. et al; "Light Chain Evolution"; Cold Spring Harbour Symp. Quant. Biol.; 1967; pages 133-146; Vol. 32	
	A09	McINTIRE, K.R. et al; "Mouse Immuglobulin Light Chains: Alteration of κ:λ Ratio"; Federal Proc.; March/April 1970; page 704; Vol. 29; No. 2; Federation of American Societies for Experimental Biology	
	A10	ARUN, S.S. et al; "Immunohistochemical Examination of Light-Chain Expression (λ/κ Ration) in Canine, Feline, equine, Bovine and Porcine Plasma Cells"; J. Vet. Med.; February 1996; pages 573-576; Vol. 43; Blackwell Wissenschafts-Verlag; Berlin, Germany	
	A11	HIETER, P. "Human Immunoglobulin κ Light-Chain Genes are Deleted or Rearranged in λ-Producing B Cells"; Nature; April 2, 1981; pages 368-372; Vol. 290; Macmillan Journals Ltd.	ļ
	A12	COLECLOUGH, C. et al; "Aberrant Rearrangements Contribute Significantly to the Allelic Exclusion of Immunoglobulin Gene Expression"; Nature; April 2, 1981; pages 372-378; Vol. 290; Macmillan Journals Ltd.	
	A13	SELSING, E et al; "Immunoglobulin λ genes"; Immuglobulin Genes Second Edition; pages 193-203; Academic Press; London, England	
	A14	BERG, J. et al; "Immunoglobulin λ Gene Rearrangement Can Precede κ Gene Rearrangement"; Developmental Immunology; 1990; Pages 53-57; Vol. 1; Harwood Academic Publishers GmbH; Great Britain	
	A15	/ ABKEN, H. et al; "Re-organization of the Immunoglobulin Kappa Gene on Both Alleles is not an Obligatory Prerequisite for Ig Lambda Gene Expression in Human Cells"; Immunology; August 12, 1991; pages 709-713; Vol. 74	

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (A) inside this box

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO 09/734,613 **Application Number** INFORMATION DISCLOSURE December 13, 2000 Filing Date STATEMENT BY APPLICANT BRUGGEMANN, Marianne First Named Inventor 1651 **Group Art Unit** Not Yet Assigned (use as many sheets as necessary) **Examiner Name** 37945-0009 **Attorney Docket Number** of Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
HILLO	A16	TAKEMORI, T. et al; "Lambda Chain Expression at Different Stages of Ontogeny in C57BL/6, BALB/c and SJL Mice"; Eur. J Immunology; 1981; pages 618-625; Vol. 11; Verlag Chemie GmbH, Weinheim, Germany	
	A17	McGUIRE ,K .et al; *κ/λ Shifts Do Not Occur During Maturation of Murine B Cells"; The Journal of Immunology; October 4, 1981; pages 1670-1673; Vol. 127, No. 4; The American Association of Immunologists; United States	ļ
, , , , , , , , , , , , , , , , , , , 	A18	KESSLER, S. et al; "Surface Membrane κ and λ Light Chain expression on Spleen Cells of Neonatal and Maturing Normal and Immune-Defective CBA/n Mice: The κ:λ Ratio is Constant"; The Journal of Immunology; October 4, 1981; pages 1674-1678; Vol. 127, No. 4; The American Association of Immunologists; United States	
<u>.</u> ,,	A19 ,	LeJEUNE, J.M. et al; "Estimate of the Light Chain Repertoire Size of Fetal and Adult BALB/CJ and CBA/J Mice, The Journal of Immunology; August 2, 1982; pages 673-677; Vol. 129; No. 2; The American Association of Immunologists: United States	
	A20	ROLINK, A. et al; "The κ/λ Ratio in Surface Immunoglobulin Molecules on B Lymphocytes Differentiating from D _H J _H -Rearranged Murine pre-B Cell Clones <i>in vitro</i> "; Eur. J. Immunol. 1991; pages 2895-2898; Vol. 21; Verlagsgesellschaft mbH; Weinheim, Germany	
	A21	OSMOND, D. et al; "Murine B Lymphopoiesis: Towards a Unified Model"; Immunology Today; February 1998; pages 65-68; Vol. 19, No. 2; Elsevier Science Ltd.; Great Britain	
	A22	ZOU et al.; "Gene Targeting in the lgκ Locus: Efficient Generation of λ Chain-Expressing B Cells, Independent of Gene Rearrangements in lgκ"; The EMBO Journal, 1993; pages 811-820; Vol. 12, No. 3; Oxford University Press	
	A23	ARAKAWA, H. et al; "ReEvaluation of the Probabilities for Productive Rearrangements on the κ and λ Loci"; International Immunology; 1996; pages 91-99; Vol. 8; No. 1; Oxford University Press	
	A24	GLOZAK, M. et al; "The Human λ Immunoglobulin Enhancer is Controlled by Both Positive Elements and Developmentally Regulated Negative Elements"; Molecular Immunology; 1996; pages 427-438; Vol. 33; No. 4/5; Elsevier Science Ltd.; Great Britain	
	A25	ASENBAUER, H. et al; "Tissue-Specific Deoxyribonuclease I-Hypersensitive Sites in the Vicinity of the Immunoglobulin C _{\(\lambda\)} Cluster of Man"; Eur. J. Immunol. 1996; pages 142-150; Vol. 26; Verlagsgesellschaft mbH; Weinheim; Germany	
	A26	GORMAN, J. et al; "The lgκ 3' Enhancer Influences the Ratio of lgκ Versus Igλ B Lymphocytes"; Immunity; September 1996; pages 241-252; Vol. 5; Cell Press	

Date Considered	iner ture
-----------------	--------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+ inside this box

Please type TRADE

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO 09/734,613 **Application Number** INFORMATION DISCLOSURE December 13, 2000 Filing Date STATEMENT BY APPLICANT BRUGGEMANN, Marianne First Named Inventor 1651 **Group Art Unit** Not Yet Assigned (use as many sheets as necessary) **Examiner Name** 37945-0009 Attorney Docket Number of 7 Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	A27	FRIPPIAT, JP. et al; "Organization of the Human Immunoglobulin Lambda Light-Chain Locus on Chromosome 22q11.2"; Human Molecular Genetics; 1995; pages 983-991; Vol. 4; No. 6; Oxford University Press	
	A28	KAWASAKI, K. et al; "One-Megabase Sequence Analysis of the Human Immunoglobulin λ Gene Locus"; Genome Research; 1997; pages 250-261; Vol. 7; Cold Spring Harbor Laboratory Press; New York, United States	
	A29	GIUDICELLI, V. et al; "IMGT, The International ImMunoGeneTics Database"; Nucleic Acids Research; 1997; pages 206-211; Vol. 25; No. 1; Oxford University Press	
	A30	IGNATOVICH, O. et al; "The Creation of Diversity in the Human Immunoglobulin V _λ Repertoire"; Journal Molecular Biology; 1997; pages 69-77; Vol. 268; Academic Press Limited	
	A31 ,	COMBRIATO, G. et al; "V _λ and J _λ -C _λ gene segments of the human immunoglobulin λ light chain locus are separated by 14 kb and rearrange by a deletion mechanism"; Eur. J. Immunol.; 1991; pages 1513-1522; Vol. 21; Verlagsgesellschaft mbH; Weinheim; Germany	
	A32	FOSTER, S. et al; "Molecular Mechanisms and Selective Influences that Shape the Kappa Gene Repertoire of IgM* B Cells"; J. Clinical Investigation; April 7, 1997; pages 1614-1627; Vol. 99; No. 7; The American Society of Clinical Investigation, Inc.	
*	A33	IGNATOVICH; O; "The Creation of Diversity in the Human Immunoglobulin V1 Repertoire" Phd. Thesis; University of Cambridge; 1998	
	A34	BRIDGES, S.L., et al; "Somatic Mutation and CDR3 Lengths of Immunoglobulin κ Light Chains Expressed in Patients with Rheumatoid Arthritis and in Normal Individuals"; The Journal of Clinical Investigation, Inc.; August 1995; pages 831-841; Vol. 96; The American Society of Clinical Investigation, Inc.	
	A35	VICTOR, K. et al; "Limited Junctional Diversity in κ Light Chains"; Journal of Immunology; 1994; pages 3467 – 3475; Vol 152; The American Association of Immunologists	
	A36	DAVIES, N. et al; "Human Antibody Repertoires in Transgenic Mice: Manipulation and Transfer of YACs"; Antibody Engineering: A Practical Approach; 1996; pages 1-35; Department of Development and Signalling; Brbraham Institute; Babraham, Cambridge; United Kingdom	
	A37	HOGAN, B. et al; "Manipulating the Mouse Embryo: A Laboratory Manual"; 1994; Cold Spring Harbor Laboratory Press; United States of America	

Examiner Signature Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this pox

MAY 2 1 2001

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction and 1995, no passens are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 7

	Complete if Known	
Application Number	09/734,613	
Filing Date	December 13, 2000	
First Named Inventor	BRUGGEMANN, Marianne	
Group Art Unit	1651	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	37945-0009	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
midalo	A38	ZOU, X. et al; "Subtle Differences in Antibody Responses and Hypermutation of λ Light Chains in Mice with a Disrupted κ Constant Region"; Eur. J. Immunology; 1995; pages 2154-2162; Vol.25; Verlagsgesellschaft mbH; Weinheim; Germany	
· · · · · · · · · · · · · · · · · · ·	A39	WURST, W. et al; "Production of Targeted Embryonic Stem Cell Clones"; Gene Targeting : A Practical Approach; 1993; pages 33-61; IRL Press; Oxford	
	A40	HERMANN, B. et al; "A Large Inverted Duplication Allows Homologous Recombination Between Chromosomes Heterozygous for the Proximal t Complex Inversion"; Cell; 1987; pages 813-825; Vol. 48	
	A41 ,	GALFRÈ, G. et al; "Preparation of Monoclonal Antibodies: Strategies and Procedures"; Methods in Enzymology; 1981; pages 3-46; Vol. 73; Academic Press, Inc.	
	A42 ,	TIJSSEN, P. et al; "Practice and Theory of Enzyme Immunoassays"; Laboratory Techniques in Biochemistry and Molecular Biology; 1985; Vol. 15. Burdon, R.H. and Knippenberg, P.H. (eds); Elsevier; Amsetrdam, The Netherlands	
	A43	CHOMCZYNSKI, P. et al; "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol- Chloroform Extraction"; Analytical Biochemistry; April 1987; pages 156-159; Vol. 162; No. 1; The Academic Press, Inc. New York, United States	:
	A44	FROHMAN, M. et al; "Rapid Production of Full-Length cDNAs from Rare Transcripts: Amplification Using a Single Gene-Specific Oligonucleotide Primer"; Proc. Natl. Acad. Sci.; December 1988; pages 8998 – 9002; Vol. 85	:
	A45	AUSUBEL, F.M. et al; "Current Protocols in Molecular Biology"; 1995; Vol. 1Wiley & Sons, United States	
.,	A46	WILLIAMS, S. et al; "Sequence and Evolution of the Human Germline V _λ Repertoire"; J. Mol. Biol.; 1996; pages 220 –232; Vol. 264; Academic Press Limited	
	A47	CHEN, J. et al; "B Cell Development in Mice that Lack One or Both Immunoglobulin κ Light Chain Genes"; The EMBO Journal; 1997; pages 821-830; Vol. 12, No. 3; Oxford University Press; United Kingdom	
	A48	BRÜGGEMANN, M. et al; "Strategies for Expressing Human Antibody Repertoires in Transgenic Mice"; Immunology Today; August 1996; pages 391-397; Vol. 17; Elsevier Sciences Ltd.	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A	/08 00
F I UI S DI VOM	しししてしし

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO 09/734,613 **Application Number INFORMATION DISCLOSURE** December 13, 2000 Filing Date STATEMENT BY APPLICANT BRUGGEMANN, Marianne First Named Inventor 1651 **Group Art Unit** Not Yet Assigned (use as many sheets as necessary) **Examiner Name** 37945-0009 Attorney Docket Number of 6 Sheet

MAY 2 1 2001

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
, made	A49	GREEN, L. et al; "Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes"; J. Exp. Med.; August 3, 1998; pages 483-495; Vol. 188; No. 3; The Rockefeller University Press	
	A50	ZOU, X. et al; "Dominant Expression of a 1.3 Mb human Igκ Locus Replacing Mouse Light Chain Production"; The FASEB Journal; August 1996; pages: 1227-1232; Vol. 10	
	A51	XIAN, J. et al; "Comparison of the Performance of a Plasmid-Based Human Igκ Minilocus and Yac-Based Human Igκ Transloci for the Production of Human Antibody Repertoires in Transgenic Mice"; Transgenic; 1998; pages 333-343; Vol. 2; OPA; Malaysia	
	A52	GONZALEZ-FERNANDEZ; A. et al; "Somatic Mutation of Immunoglobulin λ Chains: A Segment of the Major Intron Hypermutates as Much as the Complementarity – Determining Regions"; Proc. Natl. Acad. Sci.; December 1994; pages 12614-12618; Vol. 91;	
	A53	LI, Y.S. et al; "The Regulated Expression of B Lineage Associated Genes During B Cell Differentiation in Bone Marrow and Fetal Liver"; J. Exp. Med; September 1993; pages 951-960; Vol 178; The Rockefeller University Press	
	A54	HARDY, R. et al; "Resolution and Characterization of Pro-B and Pre-Pro-B Cell Stages in Normal Mouse Bone Marrow"; J. Exp. Med.; May 1991; pages 1213-1225; Vol. 173; The Rockefeller University Press	
	A55 ^	SAITTA, M. et al; "Reference Values for Immunoglobulin Kappa and Lambda Light Chains and the Kappa/Lambda Ratio in Children's Serum"; Clinical Chemistry; 1992; pages 2454-2457; Vol. 38; No. 12	
	A56	HOOD, L. et al; "Rabbit Antibody Light Chains and Gene Evolution"; Nature; December 12, 1970; pages 1040- 1044; Vol. 228	
	A57	LANSORD, R; "Mechanism and Control of Immunoglobulin Gene Rearrangement"; B.D. Hames and D.M. Glover (eds); pages 1-100; IRL Press; New York; United States	
	A58 ,	NADEL, B. et al; "Murine Lambda Gene Rearrangements: The Stochastic Model Prevails Over the Ordered Model"; The EMBO Journal; 1990; pages 435-440; Vol. 9; No. 2; Oxford University Press; United Kingdom	
	A59	ARAKAWA, H.; et al; "Re-evaluation of the Probabilities for Productive Rearrangements on the κ and λ Loci"; International Immunology; 1996; pages 91-99; Vol. 8; No. 1; Oxford University Press	

Examiner	Date Considered
Signature	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please t	vino a i	nlue eiar) (+) in:	side th	is box
LICOSO (ype a j	יפוני פטוץ		0,00	20%

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/734,613 December 13, 2000 Filing Date BRUGGEMANN, Marianne First Named Inventor **Group Art Unit** 1651 Not Yet Assigned **Examiner Name**

(use as many sheets as necessary)

37945-0009 **Attorney Docket Number** 7 of 7 Sheet

+

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	<u></u>
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
A60 /	GIUDICELLI, V. et al; "IMGT, The International ImMunoGeneTics Database"; Nucleic Acids Research; 1997; pages 206-211; Vol. 25; No. 1; Oxford University Press	
A61 /	EAGLE, H.; "Propagation in a Fluid Medium of a Human Epidermoid Carcinoma, Strain KB"; Proceedings of the Society for Experimental Biology and Medicine; 1955; pages 362-364; Vol. 89; New York	
A62	TAUB, R. et al; "Variable Amplification of Immunoglobulin λ Light-Chain Genes in Human Populations"; Nature; July 14, 1983; pages 172-174; Vol 304; Macmillan Journals Ltd.	
		-
	No. ¹ A60 A61	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. GIUDICELLI, V. et al; "IMGT, The International ImMunoGeneTics Database"; Nucleic Acids Research; 1997; pages 206-211; Vol. 25; No. 1; Oxford University Press EAGLE, H.; "Propagation in a Fluid Medium of a Human Epidermoid Carcinoma, Strain KB"; Proceedings of the Society for Experimental Biology and Medicine; 1955; pages 362-364; Vol. 89; New York TAUB R et al: "Variable Amplification of Immunoglobulin λ Light-Chain Genes in Human Populations"; Nature;

Examiner Date Signature Considered	Examiner Signature	
------------------------------------	-----------------------	--

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.